Hims & Hers Health (NYSE:HIMS) Shares Gap Up - Time to Buy?

Key Points

• Hims & Hers Health's share price gapped up from $47.79 to $50.00 at market open, trading at $49.86 with a total volume of 5,835,538 shares.
• Despite a significant revenue increase of 72.6% year-over-year, the company reported $0.17 EPS, missing analysts' expectations of $0.18.
• Analyst consensus on Hims & Hers Health is currently "Reduce" with an average price target of $38.92, as two analysts recommend buying, eight suggest holding, and three rate it a sell.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $47.79, but opened at $50.00. Hims & Hers Health shares last traded at $49.86, with a volume of 5,835,538 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. UBS Group set a $30.00 price target on Hims & Hers Health in a research note on Monday, June 23rd. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Stock Up 3.7%

The company has a market cap of $11.20 billion, a PE ratio of 61.96, a P/E/G ratio of 3.35 and a beta of 2.14. The business has a 50-day simple moving average of $50.03 and a 200-day simple moving average of $45.12. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the transaction, the chief financial officer owned 63,222 shares in the company, valued at $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 17,102 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the transaction, the insider owned 278,654 shares in the company, valued at approximately $16,649,576.50. This trade represents a 5.78% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,384,728 shares of company stock worth $71,149,098. 13.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Invesco Ltd. lifted its position in shares of Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock valued at $127,237,000 after acquiring an additional 2,128,587 shares in the last quarter. Nuveen LLC purchased a new position in Hims & Hers Health during the first quarter worth approximately $58,403,000. Clear Street LLC acquired a new position in Hims & Hers Health during the second quarter worth $83,582,000. Norges Bank purchased a new stake in Hims & Hers Health in the 2nd quarter valued at $78,464,000. Finally, Marex Group plc acquired a new stake in shares of Hims & Hers Health in the 2nd quarter worth $53,626,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.